Comparing PET/CT imaging methods in multiple myeloma patients
PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose
Oslo University Hospital · NCT03966443
This study is testing whether a new type of PET/CT scan using amino acids gives better information than the standard FDG PET/CT scan for people with multiple myeloma who may need a stem cell transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oslo University Hospital (other) |
| Locations | 1 site (Oslo) |
| Trial ID | NCT03966443 on ClinicalTrials.gov |
What this trial studies
This observational study aims to compare the imaging findings of amino acid PET/CT with FDG PET/CT in patients diagnosed with multiple myeloma. The focus is on evaluating which imaging technique provides better insights for treatment planning, particularly for those eligible for autologous stem cell transplantation (ASCT). By analyzing the results from these two imaging modalities, the study seeks to enhance diagnostic accuracy and treatment outcomes for myeloma patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with multiple myeloma who are suitable for autologous stem cell transplantation.
Not a fit: Patients with contraindications to autologous stem cell transplantation may not receive any benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved imaging techniques that enhance treatment planning for multiple myeloma patients.
How similar studies have performed: While there have been studies comparing various imaging techniques in oncology, this specific comparison of amino acid PET/CT and FDG PET/CT in multiple myeloma is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Multiple myeloma patients suitable for ASCT treatment Exclusion Criteria: * Patients with contraindications to ASCT treatment
Where this trial is running
Oslo
- Oslo University Hosptal — Oslo, Norway (RECRUITING)
Study contacts
- Study coordinator: Mona-Elisabeth Revheim, MD, PhD, MHA
- Email: monar@ous-hf.no
- Phone: +4790659373
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Myeloma, Multiple, PET-CT